Conversation with The Cancer Letter

Conversation with The Cancer Letter

What to expect: Oncology’s response to coronavirus in Italy
Conversation with The Cancer LetterCOVID-19 & CancerFree

What to expect: Oncology’s response to coronavirus in Italy
"It's like being in a war"

To get a sense of how COVID-19 will affect oncology in the U.S., The Cancer Letter called Giuseppe Curigliano, associate professor of Medical Oncology at University of Milano and the head of the Division of Early Drug Development at European Institute of Oncology, Italy, who is based in the Lombardy region—the epicenter of the outbreak.
By Alexandria Carolan
NCI’s Penberthy: We may be seeing some impact of treatment in lung cancer mortality, but we need more data
Conversation with The Cancer Letter

NCI’s Penberthy: We may be seeing some impact of treatment in lung cancer mortality, but we need more data

If the mortality rate for lung cancer is starting to fall of a cliff in part because of treatment effect—contributing to more than a third of the 2.2% decline in overall cancer mortality from 2016 to 2017—is that signal showing up on the radar of NCI's Surveillance, Epidemiology, and End Results (SEER) Program?
By Matthew Bin Han Ong
Attorney: Moffitt has made a “very irresponsible decision”—Thomas Sellers “never was a participant” in China’s Thousand Talents Program
Conversation with The Cancer Letter

Attorney: Moffitt has made a “very irresponsible decision”—Thomas Sellers “never was a participant” in China’s Thousand Talents Program

Contrary to declarations by Moffitt Cancer Center, Thomas Sellers, the institution's ousted director, was not involved in the Thousand Talents program sponsored by the People's Republic of China, said a Florida attorney who represents Sellers in preparing a lawsuit against the cancer center.
By Matthew Bin Han Ong
Learning to harmonize: Ten health care research organizations tell us how they formulated common definitions for real-world endpoints
Conversation with The Cancer LetterFreeReal-world Evidence

Learning to harmonize: Ten health care research organizations tell us how they formulated common definitions for real-world endpoints

We asked the leadership of 10 companies to share their visions of the future of data sharing, describe their portfolios in real-world evidence, and opine on what it would take to convince FDA accept real-world endpoints in regulatory decision-making in oncology.
By Matthew Bin Han Ong
Friends’ Allen: Real-world endpoints can be used to fill evidence gaps about performance of medical products
Conversation with The Cancer LetterFreeReal-world Evidence

Friends’ Allen: Real-world endpoints can be used to fill evidence gaps about performance of medical products

If real-world endpoints are indeed accurate proxies for clinical trial endpoints, real-world endpoints should start to look increasingly similar to the clinical trial endpoints as more stringent criteria are applied, said Jeff Allen, president and CEO of Friends of Cancer Research.
By Matthew Bin Han Ong